Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients.
The pharmacokinetics of isradipine, a calcium-channel blocker, have been studied in eight patients on chronic haemodialysis. A single oral dose of 5 mg was administered on both a non-haemodialysis and a haemodialysis day and the plasma concentrations of isradipine were analyzed. The mean cmax, tmax, AUC, and t1/2 in plasma on the non-haemodialysis day were 5.2 ng.ml-1, 1.4 h, 23.8 ng.h.ml-1, and 3.1 h, respectively. The dialysis clearance of isradipine was negligible (5.0 ml.min-1). The t1/2 values during haemodialysis were not significantly different from those observed during the same period post dose on the non-haemodialysis day. The study demonstrates that supplemental doses of isradipine are not necessary in these patients since isradipine is not significantly removed by haemodialysis.
Schönholzer
K
K
Dipartimento di Medicina Interna, Ospedale San Giovanni, Bellinzona, Switzerland.
Marone
C
C
D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000097:blood / Q000493:pharmacokinetics*; D002121:Calcium Channel Blockers / Q000097:blood / Q000493:pharmacokinetics*; D004095:Dihydropyridines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D017275:Isradipine; D008297:Male; D006435:Renal Dialysis; D013997:Time Factors
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D017275:Isradipine